Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 42708-013

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 42708-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qpharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (42708 013 30)

Packaging label for Atorvastatin Calcium Tablets, 20 mg, containing 30 film-coated tablets. The label indicates this is a sample not for sale and advises storing at controlled room temperature. It also shows the labeler as QPharma, Inc., Cedar Knolls, NJ, with instructions to refer to the package insert for dosage details and a space for customized dosing directions. Marked Rx Only.*

FDA Label Image

Label (42708 014 30)

Label for Atorvastatin Calcium Tablets, 10 mg, containing 30 film-coated tablets. The label includes dosing instructions with blanks for tablets, times daily, hours, and days. Distributed by QPharma, Inc., Cedar Knolls, NJ. It states storage at controlled room temperature and includes the NDC number 42708-014-30, with caution to keep the container tightly closed and out of reach of children. Sample label, not for sale.*

FDA Label Image

Figure-01 (Figure 01)

A cumulative incidence graph comparing Atorvastatin and Placebo over approximately 3.5 years. The y-axis shows cumulative incidence percentage that increases over time on the x-axis. Two curves represent Atorvastatin with a lower incidence curve and Placebo with a higher one, including a hazard ratio (HR=0.64) and p-value (0.0005) indicating statistical analysis.*

FDA Label Image

Figure-02 (Figure 02)

A line graph depicting the cumulative hazard percentage over time in years for two groups: Placebo and Atorvastatin. The graph compares the time to first primary endpoint through four years of follow-up, showing lower cumulative hazard in the Atorvastatin group compared to the Placebo group.*

FDA Label Image

Figure-03 (Figure 03)

A line graph comparing the percentage of subjects experiencing an event over time (up to 5 years) for Atorvastatin 10 mg and Atorvastatin 80 mg. The x-axis shows time in years to first major cardiovascular endpoint, and the y-axis shows the percentage of subjects. The graph includes a hazard ratio (HR 0.78) with confidence interval and p-value, indicating statistical analysis between the two dosages.*

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure diagram of atorvastatin calcium, showing the molecular composition including calcium ions associated with the atorvastatin molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.